Introduction
Methods
Identification of guideline questions
Umbrella review
Search strategy
Inclusion and exclusion criteria
Data extraction
Definitions
Analysis
Results
Critical research questions
Theme | Q | Research questions |
---|---|---|
Anticoagulant | 13 | In patients with cSDH who are not undergoing surgery (P) do antithrombotic drugs (e.g. anticoagulants, antiplatelets) (I) increase the risk of disease related complications (e.g. expansion (O) compared to those who do not take such agents (C) |
14 | In patients with cSDH who are not undergoing surgery (P) does discontinuation of antithrombotic agents (I) improve disease and safety related outcomes (O) compared to continuing these agents (C) | |
15 | In patients with cSDH (P) do antithrombotic drugs (e.g., anticoagulants, antiplatelet agents) (I) increase the risk of treatment related complications (O) compared to those who are not taking such drugs(C)? | |
16 | Does early (I) vs late (C) recommencement of anticoagulation increase the risk of recurrence or other complications (O) in patients recovering from cSDH surgery? | |
17 | In patients with cSDH scheduled for surgery who are taking an antithrombotic medication (P) what is the impact of using pharmacological or other (e.g. platelet) reversal (I) on perioperative outcomes (O) compared to standard care (C) | |
18 | In patients with cSDH who have undergone surgery (P) what is the impact of early (<72 hrs) (I) commencement of prophylactic LMWH on perioperative thromboembolic and rebleeding (incl recollection) (O) compared to standard care (C) | |
Communication and decision-making | 1 | In patients with a radiological finding of a cSDH (P) does the use of standardised tools for neurosurgical referral and intervention (I) improve patient, system, and clinical outcomes (O) compared to standard care (C) |
2 | In patients with a symptomatic, cSDH (P) does active neurosurgical management (including surgery, MME, or adjuvant medical therapies) (I) compared to conservative or medical management (C) improve patient, system, clinical outcomes (O)? | |
3 | In patients with an incidental cSDH (P) does active neurosurgical management (including surgery, MME or adjuvant medical therapies) (I) compared to conservative or medical management (C) improve patient, system, clinical outcomes (O)? | |
6 | In patients with a cSDH being discussed with a neurosurgeon (P), do standardised communication tools (e.g. structured referral proformas or decision making tools) (I) improve surgical decision making (O) compared to standard care (C)? | |
7 | In patients with cSDH being triaged for surgery (P), does the explicit identification and consideration of patient and family recovery priorities (I), improve patient, provider, and clinical outcomes (O), | |
8 | In patients with cSDH being triaged for surgery (P) does a patient and family discussion around perioperative risks and benefits led by a specialist (e.g. neurosurgeon) (I) improve patient, provider, and clinical outcomes (O) compared to a non-specialist led discussion? (C) | |
Anaesthesia and surgical scheduling | 22 | In patients undergoing surgery for cSDH (P) does the use of local anaesthesia (I) versus general anaesthesia (C) improve patient, system, and clinical outcomes (O) |
23 | In patients having surgery for cSDH (P) does protocolised or strict blood pressure control (e.g. avoidance of hypotension) (I) improve postoperative outcomes (O) compared to routine management (C) | |
24 | In patients having surgery for cSDH (P) does advanced or invasive monitoring (I) improve perioperative blood pressure control (O) compared to routine monitoring (C) | |
25 | In patients with a cSDH scheduled for surgery (P) does early surgery (I) improve patient, system, and clinical outcomes (O) compared to routine management (C) | |
26 | Do patients with a cSDH scheduled for surgery (P) who face a cancellation / delay / prolonged fasting (I) compared to those who do not (C) haved improved patient, system, and clinical outcomes (O) | |
27 | In patients with a cSDH scheduled for surgery (P) does in-hours surgery (I) improve patient, system, and clinical outcomes (O) compared to out-of hours surgery (C) | |
41 | In patients undergoing a procedural intervention for chronic subdural haematoma (P) does provision of surgical/procedural/anaesthetic care by a ‘senior’ (I) (i.e. consultant level) provider vs ‘junior’ (i.e. non-consultant level) (C) affect patient, system, and provider outcomes (O) | |
Transfer and pathway | 9 | In patients with cSDH being transferred for surgery (P) how does an optimized/protocolized transfer (I) compared to routine care (C) affect patient, system, clinical outcomes (O) |
10 | In patients with cSDH being transferred for surgery (P) does immediate transfer to tertiary centre (I) compared to routine care (C) improve patient, system, clinical outcomes (O) | |
11 | For cSDH patients (P), what is the role of technology (I) (e.g., QR codes, e-communication) compared with standard care (C) in facilitating communication between centres (incl. transfer of relevant patient information)((O | |
12 | In patients with CSDH transferred for surgery (P) does repeating blood tests (I) compared to using those communicated from original hospital (C) improve patient, system, clinical outcomes (O) | |
30 | In patients presenting to healthcare services with an undiagnosed cSDH (P) do standardised symptom checklists (I) improve time to diagnosis and treatment decision (O) compared to routine care? (C) | |
33 | In patients who have undergone interventional treatment for a cSDH and being discharged or transferred to another centre (P), do standardised communication tools (e.g. structured proformas) (I) improve patient, system, and clinical (O) compared to standard care (C)? | |
4 | In patients with a CSDH (both operative and non-operative) is their outcome (both patient and clinical) (O) improved if they receive ongoing care (e.g. rehabilitation, medical management) in a specialist (I) (neurosciences or rehabilitation facility) compared to non-specialist (secondary care) setting? | |
Perioperative care | 19 | Does the use of objective assessment tools (e.g. such as those used in Comprehensive Geriatric Assessment: frailty, cognition, multi-morbidity) to identify and optimise high-risk patients (I) in patients presenting with a cSDH (P) improve patient, system, and clinical outcomes (O) compared to standard care (C) ? |
20 | In patients with a cSDH (P) Does protocolised multidisciplinary care (e.g. co-management with a geriatrician) (I) improve patient, system, and clincial outcomes (O) compared to standard care (C)? | |
21 | Does assessing and optimising delirium risk (I) in cSDH patients who are scheduled for surgery (P) help to prevent, diagnose and treat this condition (O) compared to standard care? (C) | |
Palliative Care | 36 | In patients with a symptomatic cSDH suspected not to benefit from treatment (P) does assessment by a nominated specialist (e.g. neurosurgeon) (I) improve diagnostic accuracy, patient, and family relevant outcomes (O) compared to standard care? |
37 | Is delivery of palliative care by specialists (e.g. specialist doctor or nurse) (I) associated with improved patient and family outcomes (O) for individuals with cSDH in whom this is felt to be an end-of-life diagnosis (P) compared to non-specialist delivered care (C)? | |
Postop and recovery | 28 | Does standardised postoperative posture support and mobilisation rules (e.g. routine use of a supine position) (I) improve patient, system, and clinical outcomes (O) after cSDH surgery(P) compared to routine care (C) ? |
31 | In patients with a cSDH (both operatively and conservatively managed) (P) does the use of standardised tools to assess ongoing rehabilitation requirements (I) improve patient, system, and clinical outcomes (O) compared to standard care? | |
32 | In patients who have had interventional treatment for cSDH (P) does protocolised post-operative care and standardised discharge criteria (I) improve patient, system (e.g. time to discharge, DToC rates), and clinical outcomes (O) compared to standard care? | |
34 | In patients who have had surgery for cSDH (P) does the provision of standardised ‘red-flag’ checklists (I) improve time-to-diagnosis of symptomatic recurrence(O) compared to standard care (C) | |
4 | In patients with a CSDH (both operative and non-operative) is their outcome (both patient and clinical) (O) improved if they receive ongoing care (e.g. rehabilitation, medical management) in a specialist (I) (neurosciences or rehabilitation facility) compared to non-specialist (secondary care) setting? | |
Natural history | 29 | What factors (I) are most associated with an increased risk for developing cSDH (O) among older adults in the community (P) compared with older adults without these factors (C)? |
35 | In patients with a CSDH triaged for non-operative management (P), does active surveillance (e.g. interval CT imaging) (I) compared to expectant management (C) improve patient, system, and clinical outcomes (O) | |
Surgical technique | 38 | In patients who undergo surgical treatment for cSDH (P) does craniotomy (I) improve patient, system (e.g. time to discharge, DToC rates), and clinical outcomes (O) compared to burr holes? |
40 | In patients who undergo surgical treatment for cSDH (P) does (Drain Variation X) (I) improve patient, system (e.g. time to discharge, DToC rates), and clinical outcomes (O) compared to subdural catheter on free drainage? | |
41 | In patients undergoing a procedural intervention for chronic subdural haematoma (P) does provision of surgical/procedural/anaesthetic care by a ‘senior’ (I) (i.e. consultant level) provider vs ‘junior’ (i.e. non-consultant level) (C) affect patient, system, and provider outcomes (O) | |
MMA embolisation | 42 | In patients with an incidental cSDH (P) does MMA (I) improve patient, system (e.g. time to discharge, DToC rates), and clinical outcomes (O) compared to surveillance and risk factor modification alone? |
43 | In patients with a symptomatic cSDH (P) does MMA (I) improve patient, system (e.g. time to discharge, DToC rates), and clinical outcomes (O) compared to surgical evacuation? | |
44 | In patients with a symptomatic cSDH (P) does MMA in addition to surgery (I) improve patient, system (e.g. time to discharge, DToC rates), and clinical outcomes (in particular recurrence) (O) compared to surgical evacuation? |
Umbrella review
Baseline characteristics | Value (%) [SD] (IQR) |
---|---|
Total studies included | 73 |
Review types | Frequency |
Systematic review and meta-analysis | 50 (68.5) |
Systematic review | 22 (30.1) |
Umbrella review | 1 (1.4) |
Continent of authors | Frequency |
Asia | 29 (39.7) |
North America | 21 (28.8) |
Europe | 19 (25.8) |
Other | 4 (5.7) |
Journal | Frequency |
World Neurosurgery | 16 (21.9) |
Acta Neurochirurgica | 7 (9.6) |
Frontiers in Neurology | 5 (6.8) |
Neurosurgical Review | 3 (4.1) |
Journal of Neurotrauma | 3 (4.1) |
Medicine (Baltimore) | 3 (2.7) |
Journal of Neurosurgery | 2 (2.7) |
Journal of Clinical Neurosciences | 2 (2.7) |
Journal of Neurointerventional Surgery | 2 (2.7) |
British Journal of Neurosurgery | 2 (2.7) |
Other | 28 (38.4) |
Study details | Frequency |
Number of included studies | 13 (7–21) |
Number of included participants | 1119 [441–3149] |
Total number of included participants | 206,379 |
Review typology | Frequency |
Effectiveness | 52 (71.2) |
Prevalence and/or incidence | 3 (4.1) |
Methodological | 3 (4.1) |
Other | 15 (20.6) |
Mentioned reporting according to PRISMA | Frequency |
Yes | 56 (76.7) |
No | 17 (23.3) |
Content and domain reporting
Theme | Number of research questions (N) | Reviews identified (%) |
---|---|---|
Anticoagulant | 6 | 7 (9.6) |
Decision-making | 6 | 5 (6.8) |
Communication | 2 | 2 (2.7) |
Anaesthesia and surgical scheduling | 7 | 1 (1.4) |
Transfer | 7 | 0 (0.0) |
Perioperative care | 3 | 5 (6.8) |
Palliative care | 3 | 0 (0.0) |
Postop and recovery | 5 | 1 (1.4) |
Natural history | 2 | 21 (28.8) |
Surgical technique | 3 | 25 (34.2) |
MMA embolisation | 3 | 12 (16.4) |
AMSTAR-2 reporting quality
Item number | Description | Frequency (%) |
---|---|---|
1 | PICO description | 62 (84.9) |
2 | Review methods and protocol deviations | 24 (32.9) |
3 | Explain study designs for inclusion | 56 (76.7) |
4 | Comprehensive search strategy | 38 (52.1) |
5 | Duplicate study selection | 55 (75.3) |
6 | Duplicate data extraction | 55 (75.3) |
7 | List of excluded studies with justification | 29 (39.7) |
8 | Description of included studies | 69 (94.5) |
9 | Risk of bias for included studies | 45 (61.6) |
10 | Funding sources for included studies | 20 (27.4) |
11 | Meta-analysis statistics | 24 (32.9) |
12 | Meta-analysis risk of bias | 21 (42.9) |
13 | Risk of bias in discussion | 44 (60.3) |
14 | Explanation of heterogeneity | 48 (65.8) |
15 | Publication bias | 29 (59.2) |
16 | Conflict of interest reporting | 66 (90.4) |
Confidence rating | ||
1 | High | 7 (9.6) |
2 | Moderate | 8 (11.0) |
3 | Low | 10 (13.7) |
4 | Critically low | 48 (65.8) |